|
Please
download and print the PDF file below:
|
|
|
|
Suanne Petroff, RNCS, FNP, CNN
|
Suanne Petroff, RNCS, FNP, CNN is Director
of Nephrology Nurse Practitioners/Physician
Assistants, Western New England Renal and
Transplant Associates, Springfield, MA; and a
member of ANNA’s Colonial Chapter.
|
Despite the use of recombinant human erythropoietin (rHuEPO), anemia remains a major
problem in patients with chronic kidney disease and end stage renal disease. In addition, these
disease states are often complicated by iron deficiency, especially in patients on chronic
hemodialysis. Adequate iron supplies are necessary for normal erythropoiesis to occur and for
the patient to effectively respond to rHuEPO treatment. Therefore, it is important for the
nephrology nurse to have reliable iron test data in order to accurately monitor a patient’s iron
status. The two primary tests used to assess iron status are transferrin saturation and serum
ferritin levels. Both tests are easy to perform and are cost-efficient but have limitations and are
highly variable under certain physiologic conditions, such as inflammation and infection. Due
to these limitations, research has focused on alternative methods of iron assessment, with some
newer techniques being more effective than others. Although nephrology nurses depend on transferrin
saturation and serum ferritin levels to indicate iron status, they should recognize the associated
restrictions and treat the patient based on a complete evaluation.
|
|
CE
RELATED INFORMATION |
|
This
offering for 1.7 contact
hours is being provided by
the
American
Nephrology Nurses Association
(ANNA), which
is accredited as a provider
and approver of continuing
education in nursing by
the American Nurses
Credentialing Center-Commission
on Accreditation (ANCCCOA).
This educational activity
is approved by most states
and specialty organizations
that recognize the ANCC-COA
accreditation process. ANNA
is an approved provider of
continuing education in nursing
by the California Board of
Registered Nursing, BRN Provider
No. 00910.
|
|
Goal:
Recognize the clinical manifestations of and therapeutic options for rHuEPO-induced pure red cell aplasia (PRCA).
Objectives:
1.
Review the currently recommended strategies for assessing iron
status and their associated limitations.
2. Discuss new techniques to evaluate iron status.
3. Examine case study recommendations on how to monitor
iron-deficiency anemia.
|
AUTHOR DISCLOSURE
STATEMENT |
Suanne Petroff, RNCS, FNP, CNN has
no conflicts of interest to disclose.
|
ANNA and HDCN CE POLICY STATEMENTS |
The CE policy and disclosure statements of the American Nephrology
Nurses' Association are given in detail on the Symposium
Home Page. The CE policy statements of HDCN are listed on
this page. |